Xgeva (denosumab, AMG162)
Published: Oct 15, 2008 8:00 am
| Brand Name: | Xgeva (also marketed as Prolia) |
| Generic Name: | denosumab |
| Code Name: | AMG162 |
| Company: | Amgen |
| FDA Clinical Phase: | 2 & 3 |
Description:
Prolia is a human monoclonal antibody which is being studied in the treatment of osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma, and giant cell tumor of bone. Prolia is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal. In many bone loss conditions, RANKL overwhelms the body's natural defense against bone destruction. Prolia therefore mimics the endogenous effects of osteoprotegerin.
Clinical Trials:
For a list of clinical trials studying BI-505 for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official website for denosumab: http://www.amgen.com/science/pipe_denosumab.html
Source: Wikipedia, Denosumab, http://en.wikipedia.org/wiki/Denosumab (as of November 14, 2009)
Related Articles:
- FDA Approves Once-Weekly Dosing And Revised Safety Information For Kyprolis
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma
- Sustained Complete Response To Initial Treatment Associated With Substantial Survival Benefit In Multiple Myeloma
- Getting To Know: Tiragolumab
- Getting To Know: TNB-383B
